945756-15-0

Basic information

• Product Name: N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)acetamide
• Synonyms: N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)acetamide
• CAS NO: 945756-15-0
• Molecular Weight: 261.711
• Mol File: 945756-15-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)acetamide(945756-15-0)
• EPA Substance Registry System: N-(4-(2-chloro-5-methylpyrimidin-4-yl)phenyl)acetamide(945756-15-0)

Safety Data

• Hazardous Substances Data: 945756-15-0(Hazardous Substances Data)

Upstream product

• 103-88-8 4-bromoacetanilide 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 214360-60-8 N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide 
• 106-40-1 4-bromo-aniline 
• 101251-09-6 (4-acetylaminophenyl)boronic acid 

Relevant articles and documents

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat

Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments. Being able to do this via two targeted pathways without inducing side effects through a general mechanism, such as chemotherapy, could bring benefit to patients. In this work we describe a new dual inhibitor of the JAK-STAT and HDAC pathways through designing and developing two types of molecule based on the JAK2 selective inhibitor XL019 and the pan-HDAC inhibitor, vorinostat. Both series of compounds had examples with low nanomolar JAK2 and HDAC1/6 inhibition. In some cases good HDAC1 selectivity was achieved while retaining HDAC6 activity. The observed potency is explained through molecular docking studies of all three enzymes. One example, 69c had 16–25 fold selectivity against the three other JAK-family proteins JAK1, JAK3 and TYK2. A number of compounds had sub-micromolar potencies against a panel of 4 solid tumor cell lines and 4 hematological cell lines with the most potent compound, 45h, having a cellular IC50 of 70 nM against the multiple myeloma cell line KMS-12-BM. Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated. Evidence of apoptosis with two compounds in 4 sold tumor cell lines is also presented.

4-ARYL-2-AMINO-PYRIMIDINES OR 4-ARYL-2-AMINOALKYL-PYRIMIDINES AS JAK-2 MODULATORS AND METHODS OF USE

This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R1, R2, R25, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.